← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
GORDON CARL L
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001282930
Purchase history
- Companies traded
- 5
- Purchases · 12M
- 4
- Purchases · 24M
- 5
- Average purchase
- $12.6M
- Median purchase
- $15.0M
- Gross purchase value
- $63.2M
Companies: ADARx Pharmaceuticals, Inc. | BlossomHill Therapeutics, Inc. | Electra Therapeutics, Inc. | MBX Biosciences, Inc. | Scribe Therapeutics, Inc.
5 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-09-30 | ADARx Pharmaceuticals, Inc. | ADRX | Director | 10% Owner | $16.1M | Open filing |
| 2026-09-23 | Electra Therapeutics, Inc. | ETRA | Director | 10% Owner | $20.0M | Open filing |
| 2026-08-12 | BlossomHill Therapeutics, Inc. | BLSM | Director | $10.0M | Open filing |
| 2026-07-29 | Scribe Therapeutics, Inc. | SCTX | Director | $15.0M | Open filing |
| 2025-02-19 | MBX Biosciences, Inc. | MBX | Director | 10% Owner | $2.0M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 4Small Sample | 80.0% (4/5) | 50.0% (2/4) | -5.3% | -0.4% | -15.0% |
| 20D | 2Small Sample | 66.7% (2/3) | 100.0% (2/2) | +51.0% | +51.0% | +34.3% |
| 60D | 0No Data | 0.0% (0/1) | — | — | — | — |
| 120D | 0No Data | 0.0% (0/1) | — | — | — | — |
Research patterns
- First purchase in 12M
- 4/4
- Large purchase ≥ $100k
- 5/5
- Cluster buying · 15D
- 5/5
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.